Press releases
2020
Guard Therapeutics (Nasdaq First North Growth Market: GUARD) has today presented follow-up results from a previously completed phase 1 study of ROSgard in single ascending doses (SAD). In particular, the results show that the investigational drug has a favourable effect on a well established biomarker that is used to predict onset of acute...
Guard Therapeutics has today announced that Peter Gilmour has been appointed Head of Preclinical Science. He has extensive experience in drug discovery and clinical drug development from leading positions at global pharmaceutical companies. Peter Gilmour will be part of the company’s management team and will take up his post on 1 August...
17 March, 2020
Guard Therapeutics International AB: Guard Therapeutics announces positive top line results from a clinical phase 1a study of ROSgard
2019
23 September, 2019
Redeye initiates coverage of A1M Pharma
We initiate coverage of A1M Pharma, a early stage biotech company developing a candidate to treat acute kidney injuries in associating with cardiac surgery. With a history of disappointment we now see real potential in A1M Pharma with their new management and strategy as they move towards meeting an unmet medical need. With a strong owner...